The incidence of opioid use disorder among people with acute and chronic pain managed with prescription opioids in the United States: economic and societal burden [0.03%]
美国急性及慢性疼痛患者在使用处方阿片类药物治疗过程中发生阿片类物质使用障碍的发病率：经济和社会负担
Andrew J Schoenfeld,Sushanth Jeyakumar,Jessica Morlando Geiger et al.
Andrew J Schoenfeld et al.
Aims: This retrospective, longitudinal, observational study evaluated the incidence of opioid use disorder (OUD) among patients newly initiating opioids to manage acute and chronic pain in the United States. Additionally,...
Observational Study
Journal of medical economics. 2026 Dec;29(1):1355-1371. DOI:10.1080/13696998.2026.2655086 2026
Correction [0.03%]
改正
Published Erratum
Journal of medical economics. 2026 Dec;29(1):1420. DOI:10.1080/13696998.2026.2668135 2026
Clinical burden and healthcare resource utilization after allogeneic hematopoietic stem cell transplant for sickle cell disease or β-thalassemia [0.03%]
异基因造血干细胞移植治疗镰状细胞病或β-地中海贫血的临床负担和医疗资源利用状况
Duncan Brown,Nanxin Li,Jiahe Li et al.
Duncan Brown et al.
Introduction: Allogeneic hematopoietic stem cell transplant (allo-HSCT) is a potentially curative treatment for patients with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or β-thalassemia. Real-w...
Medical costs attributable to obesity and obesity-related health disorders in a Japanese population using JMDC claims database [0.03%]
基于日本医疗数据库的肥胖及其相关健康状况所致的医疗费用支出
Taisuke Kojima,Satoshi Osaga,Toshihiko Aranishi et al.
Taisuke Kojima et al.
Aim: This study aimed to estimate the medical costs attributable to obesity among Japanese adults with obesity-related health disorders using the JMDC claims database and assess the impact of body mass index (BMI) categor...
Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and Canada [0.03%]
高级帕金森病（aPD）皮下左旋多巴/卡比多巴（LDp/CDp）的社会成本影响分析（英国、法国、德国、西班牙和加拿大）
K Ray Chaudhuri,Juan Carlos Parra,Trishal Boodhna et al.
K Ray Chaudhuri et al.
Background: The costs associated with advanced Parkinson's disease (aPD) extend beyond direct medical expenditure. As symptoms become more severe, professional and informal personal care costs are likely to exceed those i...
Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy [0.03%]
意大利用于治疗阳性非小细胞肺癌的一线药物洛拉替尼的成本效益分析(ALK)
Ilaria Valentini,Filippo Rumi,Eugenio Di Brino et al.
Ilaria Valentini et al.
Background: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with high central nervous system penetration and activity against resistance mutations. Although its clinical e...
Addressing the challenges of health economic modelling in the context of suboptimal evidence base - case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer [0.03%]
次优证据背景下卫生经济学面临的挑战及应对措施——以非肌层浸润性膀胱癌窄带成像与光动力学诊断为例的实证研究分析
Jonathan Belsey,Wojciech Chrosny,Jane Lapon
Jonathan Belsey
Introduction: Standard economic models, which have been developed to reflect typical data availability for pharmaceutical products, often struggle with non-pharmaceutical interventions like diagnostics and medical devices...
Comparative Study
Journal of medical economics. 2026 Dec;29(1):1341-1354. DOI:10.1080/13696998.2026.2661553 2026
Response to Kirshner et al.: updated cost consequence analyses using requested inputs [0.03%]
对Kirshner等人的回应：使用请求输入的最新成本影响分析
Vanessa Perez Patel,Kevin Collins,Klaas Heinemann et al.
Vanessa Perez Patel et al.
Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia [0.03%]
阿特珠单抗和贝伐珠单抗作为马来西亚不可切除肝细胞癌一线全身治疗的性价比分析
Yoke Fui Wong,Rosmawati Mohamed,Audi Adawiah Sulaiman Shah et al.
Yoke Fui Wong et al.
Aim: This study aims to evaluate the cost-effectiveness of atezolizumab plus bevacizumab as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) in Malaysia, compared with the current standard trea...